Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

NCT00555724 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Biogen